id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-275110-safr9z37	Alexander, Paul Elias	COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine	2020-04-21		.txt	text/plain	3337	169	45	At this time, more than ever, the high-quality, robust, comparative evidence from ethical randomized controlled trials (RCTs) is urgently needed to assess patient-important outcomes, including mortality, morbidity, need for life support, safety, and toxicity, informing on the safe use of chloroquine or hydroxychloroquine (with and without azithromycin) in people with COVID-19. This issue of potential harmful effects and the urgent need for high-quality, methodologically robust studies also comes from a recent pre-publication (not yet peer-reviewed) of in vitro activity of hydroxychloroquine or chloroquine in combination with metformin (used in treatment of type 2 diabetes to lower blood sugar in humans) in mice (25) . The use of existing drug treatments such as chloroquine and hydroxychloroquine outside of current guidelines and recommendations may result in adverse effects, including serious illness and death, affect patients with other diseases who may benefit from its use, and hinder the ability to conduct clinical trials if there are high demands to sue these agents by clinicians and patients.	./cache/cord-275110-safr9z37.txt	./txt/cord-275110-safr9z37.txt